- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- FDA's Janet Woodcock not to retire
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
PHILADELPHIA — The Food and Drug Administration has approved a generic drug for obesity made by Lannett, the drug maker said Tuesday.
Lannett announced the approval of phentermine hydrochloride capsules in the 15-mg strength.
Various versions of the drug had sales of $11 million at average wholesale price in 2011, according to Wolters Kluwer.